Advances in the Treatment of Advanced Non-Small Cell Lung Cancer

  • Chen X
  • Guo J
  • Guo M
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

In recent years, the incidence of lung adenocarcinoma has been increasing, and now it has become the largest type of non-small cell lung cancer (NSCLC). Currently, treatment of advanced NSCLC consists of several modalities: systemic chemotherapy, local radiation therapy, and targeted therapy (including most recently immunotherapy). In the past decade, the discovery of new molecular subtypes, the search for tumor driver gene mutations, the development of targeted molecular targeted drugs, or targeted therapy to suppress tumor angiogenesis and regulate tumor immune response have been the main directions of NSCLC research and clinical diagnosis and treatment. At present, platinum-based chemotherapy is widely used in NSCLC patients clinically. Platinum-based chemotherapy drugs can effectively prolong the survival time of patients and improve their quality of life, but the incidence of adverse reactions is still high. Therefore, it is necessary to find a drug that can improve the efficacy of patients and reduce the adverse reactions of platinum chemotherapy drugs to NSCLC patients.

Cite

CITATION STYLE

APA

Chen, X., Guo, J., & Guo, M. (2020). Advances in the Treatment of Advanced Non-Small Cell Lung Cancer. Advances in Lung Cancer, 09(02), 30–40. https://doi.org/10.4236/alc.2020.92004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free